Key SURVEYOR-I Eligibility Criteria
Inclusion  Male or female between 18 and 70 years of age, inclusive, at time of screening.  Screening laboratory result indicating HCV GT1 infection.  Chronic HCV infection defined as one of the following:
o Positive for anti-HCV antibody (Ab) or HCV RNA at least 6 months before screening, and positive for HCV RNA and anti-HCV Ab at the time of screening; or o Positive for anti-HCV Ab and HCV RNA at the time of Screening with a liver biopsy consistent with chronic HCV infection (or a liver biopsy performed prior to enrollment with evidence of chronic HCV infection).
 Patient must meet one of the following criteria: o Treatment-naïve: patient has never received treatment for HCV infection. o Peginterferon/ribavirin experienced:  On-treatment failure: patient received PR for the treatment of HCV, did not discontinue due to intolerance or an adverse event, and failed to achieve an undetectable HCV RNA at the end of PR treatment; or  Relapse: patient received anti-HCV therapy with PR, did not discontinue due to intolerance or an adverse event, and had detectable HCV RNA during treatment follow-up. 
Virologic Stopping and Futility Criteria
Patients were required to stop treatment with study drugs if they met any of the following criteria:
 Confirmed increase from nadir in HCV RNA, defined as 2 consecutive HCV RNA measurements (>1 log 10 IU/mL above nadir) at any time point during treatment.  Failure to achieve unquantifiable HCV RNA levels by week 6.  Confirmed quantifiable HCV RNA level at any point after an unquantifiable level.
Supplemental Table 1. Baseline NS3 and NS5A Substitutions Detected in Patients with HCV Genotype 1 Infection
Genotype 1 ABT-493 200 mg ABT-530 120 mg N = 27 NS3 substitutions, n (%) V55A 2 (7) Q80K 4 (15) S122G 2 (7) I170V 4 (15) NS5A substitutions, n (%) M28V 2 (7) Q30R 1 (4) R30Q (GT1b)* 1 (4) L31M
1 (4) GT, genotype. * Only 1 GT1b-infected patient had a baseline HCV sequence substitution; all other substitutions were found in GT1a-infected patients. Baseline substitutions were detected by population sequencing (threshold for detection ~15%). NS3 protease or NS5A inhibitor baseline resistance-associated substitutions for HCV GT1 are more clearly defined than other genotypes and were assessed based on the specific amino acid substitutions at the signature positions described below. GT1 NS3 substitutions: 
